(NASDAQ: VNDA) Vanda Pharmaceuticals's forecast annual revenue growth rate of 22.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Vanda Pharmaceuticals's revenue in 2025 is $201,351,000.On average, 2 Wall Street analysts forecast VNDA's revenue for 2025 to be $13,407,594,655, with the lowest VNDA revenue forecast at $13,378,127,414, and the highest VNDA revenue forecast at $13,437,061,896. On average, 2 Wall Street analysts forecast VNDA's revenue for 2026 to be $17,871,881,667, with the lowest VNDA revenue forecast at $16,884,729,093, and the highest VNDA revenue forecast at $18,859,034,240.
In 2027, VNDA is forecast to generate $21,605,381,101 in revenue, with the lowest revenue forecast at $21,605,381,101 and the highest revenue forecast at $21,605,381,101.